Keywords: آبستر استات; abiraterone acetate; castration-resistant prostate cancer; combined androgen blockade;
مقالات ISI آبستر استات (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آبستر استات; ARSIs; androgen receptor signaling inhibitors; AA; abiraterone acetate; AR; androgen receptor; BPH; benign prostatic hyperplasia; CNV; copy number variation; CRPC; castration resistant prostate cancer; CTC; circulating tumor cells; ctDNA; cell-free circul
Keywords: آبستر استات; Prostate cancer; Bisphosphonates; Abiraterone acetate; Denosumab; Zoledronic acid; Enzalutamide; Radium-223;
Keywords: آبستر استات; Abiraterone acetate; mCRPC; Progression-free survival; PSA decline; PSA flare;
Keywords: آبستر استات; Abiraterone acetate; Androgen deprivation therapy; Castration-resistant prostate cancer; Metastatic prostate cancer; Patient reported outcomes;
Keywords: آبستر استات; Abiraterone acetate; Androgen receptor; Metastatic castration-resistant prostate cancer; Prostate-specific antigen; Urology expert;
Keywords: آبستر استات; Abiraterone acetate; Trough concentration; PSA response; Metastatic castration-resistant prostate carcinoma; Drug monitoring;
Keywords: آبستر استات; Cáncer de próstata resistente a la castración; Tratamiento; Acetato de abiraterona; Quimioterapia sistémica; Supervivencia; Factores pronóstico; Castration-resistant prostate cancer; Treatment; Abiraterone Acetate; Systemic chemotherapy; Survival; Pr
Keywords: آبستر استات; Abiraterone acetate; Adverse events; Corticosteroids; Glucocorticoid; Long term; Metastatic castration-resistant prostate cancer; Tolerability;
Keywords: آبستر استات; Abiraterone acetate; Metastatic castration-resistant prostate cancer; Prostate-specific antigen;
Keywords: آبستر استات; abiraterone acetate; abiraterone; intestinal absorption; human intestinal fluids; clinical trial; food effect; supersaturation;
Keywords: آبستر استات; Prostate neoplasms; Castration-resistant; Biomarkers; Receptors; Androgen; Genetic; Abiraterone acetate; MDV 3100; Docetaxel; Cabazitaxel
Keywords: آبستر استات; Abiraterone acetate; Androgen receptor antagonists; Gonadotropin-releasing hormone; Prednisone; Prostate cancer;
Keywords: آبستر استات; Triple negative breast cancer; Androgen receptor; Bicalutamide; Enzalutamide; Abiraterone acetate; Seviteronel;
Keywords: آبستر استات; Prostate cancer; Abiraterone acetate; Enzalutamide; Orteronel;
Keywords: آبستر استات; Abiraterone acetate; Prostate cancer; Castration-resistant prostate cancer; ECOG; Performance status;
Keywords: آبستر استات; Metastatic castration-resistant prostate cancer; Docetaxel; Young; Abiraterone acetate; Cabazitaxel; Enzalutamide;
Keywords: آبستر استات; Enzalutamide; Abiraterone acetate; Abiraterone; Docetaxel; Castration-resistant prostate cancer
Keywords: آبستر استات; Prostate cancer; Cabazitaxel; Abiraterone acetate; Enzalutamide; Sequential therapy
Keywords: آبستر استات; AA; abiraterone acetate; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; AR splice variant; CRPC; castration-resistant prostate cancer; CTC; circulating tumor cell; CYP; cytochrome P450; FDA; Food and Drug Administration; LBD; ligand-bindi
Keywords: آبستر استات; Abiraterone acetate; Metastatic castration-resistant prostate cancer; Secondary hormonal therapy; New hormonal therapies; CYP17; 17α-Hydroxylase; Abiraterona acetato; Cáncer de próstata resistente a la castración; Terapia hormonal secundaria; Nuevas t
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
Keywords: آبستر استات; Abiraterone acetate; Metastatic castrate-resistant prostate cancer; Pain; Quality of life; Radium-223 dichloride;
Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan
Keywords: آبستر استات; Abiraterone acetate; CRPC; Docetaxel; Enzalutamide; Oncological outcome;
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score
Keywords: آبستر استات; Abiraterone acetate; Metastatic castration-resistant prostate cancer; Stratification; Prognostic discrimination; Predictive parameters;
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study
Keywords: آبستر استات; Abiraterone Acetate; Castration-Resistant Prostate Cancer; Chemo-Naïve; Chemotherapy; Metastasis;
Abiraterone acetate in the treatment of prostate cancer
Keywords: آبستر استات; Abiraterone acetate; Prostate; Cancer; Therapeutics;
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for â¥24 weeks in Europe
Keywords: آبستر استات; Abiraterone acetate; Enzalutamide; Metastatic castration-resistant prostate cancer;
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis
Keywords: آبستر استات; Abiraterone acetate; Combined modality therapy; Docetaxel; Quality of life; Network meta-analysis; Prostatic neoplasms; Survival;
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Keywords: آبستر استات; Abiraterone acetate; Androgen signaling-directed therapy; Chemotherapy-naïve; Metastatic castration-resistant prostate cancer; Sequencing;
Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide
Keywords: آبستر استات; Castration-resistant prostate cancer; Abiraterone acetate; Enzalutamide; Time to PSA nadir;
Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer
Keywords: آبستر استات; Abiraterone acetate; Cross-resistance; Docetaxel; Enzalutamide; Progression-free survival;
Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Keywords: آبستر استات; Abiraterone acetate; Cross-resistance; Enzalutamide; Sequential therapy;
Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements
Keywords: آبستر استات; AA; abiraterone acetate; API; active pharmaceutical ingredient; FaSSIF/FeSSIF; fasted/fed state simulated intestinal fluid; PAMPA; parallel artificial membrane permeation assay; S.D.; standard deviation; HPLC; high performance liquid chromatography; DLS;
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Keywords: آبستر استات; Abiraterone acetate; Docetaxel; Elderly; Metastatic castration-resistant prostate cancer; Subsequent therapy; Treatment patterns;
Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistan
Keywords: آبستر استات; Abiraterone acetate; Docetaxel; Enzalutamide; mCRPC; Sequential treatment;
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
Keywords: آبستر استات; Abiraterone acetate; Androgen receptor; Docetaxel; Combination; Drug-drug interaction; Metastatic castration-resistant prostate cancer; Pharmacokinetics; Safety; Toxicity;
Original articleThe efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
Keywords: آبستر استات; abiraterone acetate; docetaxel; metastatic castration-resistant prostate cancer; prednisolone; prostate-specific antigen;
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
Keywords: آبستر استات; Prostatic neoplasms; Castration-resistant; Abiraterone acetate; Compassionate use; Docetaxel;
A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer
Keywords: آبستر استات; Abiraterone acetate; Metastatic castration-resistant prostate cancer; Routine practice; Efficacy;
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice
Keywords: آبستر استات; Abiraterone acetate; Castration-resistant prostate cancer; Bone metastasis; Bone Scan Index;
Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis
Keywords: آبستر استات; abiraterone acetate; enzalutamide; metastatic castration-resistant prostate cancer;
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials
Keywords: آبستر استات; Prostate cancer; Orteronel; Abiraterone acetate; Safety; Mineralcorticoid events;
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
Keywords: آبستر استات; Abiraterone acetate; Cabazitaxel; Castration-resistant prostate cancer; Enzalutamide; Fourth line; Prognostic factors; Third line;
Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
Keywords: آبستر استات; Abiraterone acetate; Bone-targeted therapy; Chemotherapy-naïve; Metastatic castration-resistant prostate cancer;
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Keywords: آبستر استات; Prostate cancer; PTEN; Abiraterone acetate; Immunohistochemistry;
Évaluation de la réponse métabolique en TEP/TDM à la F18-FCH après un mois de traitement par acétate d’abiratérone chez les patients présentant un cancer de la prostate métastatique résistant à la castration
Keywords: آبستر استات; CPRC; Cancer prostatique; Métastase ganglionnaire; Métastase osseuse; Acétate d’abiratérone; TEP-TDM; 18F-FCH; SUVpeak; SUVmax; Hétérogénéité de réponse; PSA; Évaluation thérapeutiquemCRPC; Lymph nodes and bone metastases; Abiraterone acetate; 18F-choline
Abiraterone-What Is Wrong With the Adrenal Glands?
Keywords: آبستر استات; Abiraterone acetate; Adrenal gland metastases; Metastatic castration-resistant prostate cancer; Steroid switch; Visceral disease;
Enzalutamide, modalités pratiques d'utilisation d'une nouvelle hormonothérapie
Keywords: آبستر استات; cancer de la prostate hormono-réfractaire métastatique; récepteur aux androgènes; acétate d'abiratérone; MDV3100; enzalutamide; metastatic hormone-refractory prostate cancer; androgen-receptor; abiraterone acetate; MDV3100; enzalutamide;
Acétate d'abiratérone (AA) : comment prescrire l'abiratérone et à qui en 2014 ?
Keywords: آبستر استات; acétate d'abiratérone; cancer de la prostate résistant à la castration; cytochrome CYP17; androgenèse; abiraterone acetate; castration-resistance prostate cancer; cytochrome CYP17; steroidogenosis;
Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy
Keywords: آبستر استات; Abiraterone acetate; Elderly; Metastatic castration-resistant prostate cancer